QPPV.COM KNOWLEDGE ASSESSMENT

How the EU Medicines Regulatory System Works

Test your understanding of the concepts covered by How the EU Medicines Regulatory System Works.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the principal role of the Reference Member State in MRP and DCP?

To adopt the European Commission's Union decision To coordinate or conduct the principal assessment and prepare the assessment documentation To act as the sole enforcement authority for all participating countries To replace the Concerned Member States' legal authorities

Question 2 of 10 What is the most useful practical framework for classifying a new EU medicines regulatory question?

Identify the product, authorisation status, legal basis, responsible body, evidence and operative outcome Start with the most familiar committee and infer the remaining details Focus only on whether the issue is safety-related Select the shortest available procedure before reviewing the evidence

Question 3 of 10 Which sequence most appropriately represents the distinction between scientific assessment and legal decision-making?

Legal decision, evidence generation, scientific assessment, implementation Evidence, scientific assessment, committee opinion or recommendation, legally operative decision where required, implementation Implementation, committee opinion, national authorisation, evidence generation EMA webpage, applicant communication, automatic legal effect

Question 4 of 10 A company is assessing which EU procedure applies to a new regulatory issue. What should it establish first?

Which agency website contains the most recent document Which committee has the most prominent role in the issue The product status, legal basis and procedural trigger Whether the issue has received media attention

Question 5 of 10 What does the existence of different EU authorisation routes primarily determine?

Whether the product must meet a lower or higher scientific standard How assessment is organised, how Member States participate and where the authorisation is legally effective Whether pharmacovigilance obligations apply after authorisation Whether the product requires evidence of quality

Question 6 of 10 Which statement most accurately describes the MAH's position after authorisation?

The MAH transfers its regulatory responsibilities to EMA once the product is authorised The MAH remains responsible for applicable obligations, including pharmacovigilance, quality, regulatory submissions and risk management The MAH is responsible only for commercial distribution The MAH has no role in product-information maintenance

Question 7 of 10 A new manufacturing process may affect the quality profile of a medicine and potentially its clinical performance. What regulatory principle does this illustrate?

Quality, safety and efficacy can be assessed as completely unrelated dimensions Manufacturing changes are outside the medicines regulatory lifecycle The traditional regulatory pillars are interdependent and may require integrated assessment Only pharmacovigilance evidence can justify regulatory action

Question 8 of 10 Which situation best demonstrates why pharmacovigilance and regulatory affairs must interact?

A safety finding may require changes to product information, the RMP or risk-minimisation measures Pharmacovigilance findings are relevant only to scientific publications Regulatory decisions cannot create new pharmacovigilance obligations Product-information changes are unrelated to safety assessments

Question 9 of 10 Why is the statement 'EMA approved the medicine' imprecise in formal regulatory writing?

EMA has no role in centralised applications CHMP, rather than EMA, is the only body with legal authority to authorise medicines EMA coordinates scientific assessment, while the European Commission adopts the legally binding centralised decision National authorities always issue the final centralised authorisation

Question 10 of 10 Which statement best distinguishes a national authorisation from a centralised authorisation?

A national authorisation is outside the common EU scientific and legal framework A national authorisation initially applies within an individual Member State, while a centralised authorisation is a Union authorisation A national authorisation is subject only to safety requirements, not quality and efficacy requirements A centralised authorisation is granted by the RMS on behalf of all Member States

How the EU Medicines Regulatory System Works

Cookie Settings